Prolactin Levels and Sexual Adverse Effects in Patients With Schizophrenia During Antipsychotic Treatment
Authors:
- Maria A. RettenbacherMRMaria A. Rettenbacher
- Alex HoferAHAlex Hofer
- Christoph EbenbichlerCEChristoph Ebenbichler
- Susanne BaumgartnerSBSusanne Baumgartner
- Monika EdlingerMEMonika Edlinger
- Julia EnglJEJulia Engl
- Susanne KaserSKSusanne Kaser
- Georg KemmlerGKGeorg Kemmler
- Peter MalikPMPeter Malik
- Alexander TschonerATAlexander Tschoner
- Walter Wolfgang FleischhackerWFWalter Wolfgang Fleischhacker
- 1 December 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 30 (6) , 711-715
Abstract
Patients with schizophrenia often experience sexual dysfunction (SD), to which disorder-related factors like negative symptoms and nondisorder-related factors can theoretically contribute. Thus, we investigated the correlation of SD and serum prolactin level in patients with schizophrenia during antipsychotic treatment. We included 39 patients with schizophrenia with a mean age of 34.6 years who were switched to second-generation antipsychotics into the study. Sexual adverse effects (via a specific scale) and serum prolactin levels were measured at baseline and week 4. In males, mean prolactin levels increased over 4 weeks at a trend level of significance. Although a high incidence of SD was reported at baseline, there were no statistically significant changes over the course of 4 weeks. At baseline, a positive correlation between diminished sexual desire and prolactin levels could be found in men, which was not found in women; at week 4, both male and female patients demonstrated a positive correlation between orgastic dysfunction and prolactin levels. We found significant positive correlations between changes in prolactin levels over 4 weeks and changes in orgastic dysfunction for both sexes. Regression analyses showed prolactin levels at baseline to be a predictor of diminished sexual desire in men. Change in prolactin level was found to be a predictor of change for diminished sexual desire in women and for orgastic dysfunction in both sexes. We conclude that the potential of antipsychotics to increase serum prolactin levels imposes a certain risk that patients will experience SD of varying severity.Keywords
This publication has 17 references indexed in Scilit:
- Changes in Sexual Function for Outpatients With Schizophrenia or Other Psychotic Disorders Treated With Ziprasidone in Clinical Practice SettingsJournal of Clinical Psychopharmacology, 2008
- Nicotine consumption and schizotypy in first-degree relatives of individuals with schizophrenia and non-psychiatric controlsSchizophrenia Research, 2007
- Sexual functioning, psychopathology and quality of life in patients with schizophreniaSchizophrenia Research, 2007
- Sexual Dysfunction in Psychiatric Inpatients The Role of Antipsychotic MedicationPharmacopsychiatry, 2007
- The Level of Cardiovascular Risk Factors in Bipolar Disorder Equals That of SchizophreniaThe Journal of Clinical Psychiatry, 2007
- A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophreniaJournal of Psychopharmacology, 2007
- A Randomized Open-Label Study of the Impact of Quetiapine Versus Risperidone on Sexual FunctioningJournal of Clinical Psychopharmacology, 2004
- Nithsdale Schizophrenia Surveys 24: sexual dysfunctionThe British Journal of Psychiatry, 2003
- Sexual dysfunction in patients taking conventional antipsychotic medicationThe British Journal of Psychiatry, 2002
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987